StockAnalyst
/
GSK strikes up to $750 million deal for cancer-targeting drug

GSK strikes up to $750 million deal for cancer-targeting drug

来源：Reuters发布于 2026-09-15

GSK said on Tuesday it had agreed a deal worth up to $750 million ​to buy a trispecific T cell-engager (TCE), a drug ‌designed to help T-cells target cancer, from China-based biotechnology firm Chimag...

相关标的：GSK
继续访问返回新闻

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。